236 related articles for article (PubMed ID: 21415221)
1. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
[TBL] [Abstract][Full Text] [Related]
2. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
3. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Dreyling M
Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
[No Abstract] [Full Text] [Related]
4. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
7. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
8. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
Owen RG; Kyle RA; Stone MJ; Rawstron AC; Leblond V; Merlini G; Garcia-Sanz R; Ocio EM; Morra E; Morel P; Anderson KC; Patterson CJ; Munshi NC; Tedeschi A; Joshua DE; Kastritis E; Terpos E; Ghobrial IM; Leleu X; Gertz MA; Ansell SM; Morice WG; Kimby E; Treon SP;
Br J Haematol; 2013 Jan; 160(2):171-6. PubMed ID: 23150997
[TBL] [Abstract][Full Text] [Related]
9. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Marchand T; Tas P; Houot R; Dauriac C; Lamy T; Cahu X
Eur J Haematol; 2011 Jul; 87(1):98. PubMed ID: 21418108
[No Abstract] [Full Text] [Related]
11. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
13. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
14. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
15. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
Paiva B; Martinez-Lopez J; Vidriales MB; Mateos MV; Montalban MA; Fernandez-Redondo E; Alonso L; Oriol A; Teruel AI; de Paz R; Laraña JG; Bengoechea E; Martin A; Mediavilla JD; Palomera L; de Arriba F; Bladé J; Orfao A; Lahuerta JJ; San Miguel JF
J Clin Oncol; 2011 Apr; 29(12):1627-33. PubMed ID: 21402611
[TBL] [Abstract][Full Text] [Related]
17. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
Banwait R; O'Regan K; Campigotto F; Harris B; Yarar D; Bagshaw M; Leleu X; Leduc R; Ramaiya N; Weller E; Ghobrial IM
Am J Hematol; 2011 Jul; 86(7):567-72. PubMed ID: 21681781
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib plus melphalan and prednisone for multiple myeloma.
Avvisati G
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
[No Abstract] [Full Text] [Related]
20. Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss L; Melchardt T; Neureiter D; Kemmerling R; Moshir S; Pleyer L; Greil R; Egle A
J Clin Oncol; 2011 Aug; 29(24):e696-8. PubMed ID: 21730268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
